TWD 24.2
(-0.21%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 492.4 Million TWD | -23.86% |
2022 | 646.72 Million TWD | -3.37% |
2021 | 669.25 Million TWD | -1.96% |
2020 | 682.63 Million TWD | -14.72% |
2019 | 800.51 Million TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | 397.85 Million TWD | 3.08% |
2024 Q1 | 413.75 Million TWD | -15.97% |
2023 Q3 | 477.75 Million TWD | -29.85% |
2023 FY | 492.4 Million TWD | -23.86% |
2023 Q1 | 667.13 Million TWD | 3.16% |
2023 Q2 | 681.09 Million TWD | 2.09% |
2023 Q4 | 492.4 Million TWD | 3.07% |
2022 Q3 | 634.26 Million TWD | 0.0% |
2022 Q4 | 646.72 Million TWD | 1.97% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Allied Biotech Corporation | 178.11 Million TWD | -176.457% |
GeneFerm Biotechnology Co., Ltd. | 31.92 Million TWD | -1442.335% |
Easywell Biomedicals, Inc. | 123.43 Million TWD | -298.913% |
TTY Biopharm Company Limited | -705.97 Million TWD | 169.748% |
Synmosa Biopharma Corporation | 1.52 Billion TWD | 67.633% |
Orient EuroPharma Co., Ltd. | 3.1 Billion TWD | 84.148% |
Center Laboratories, Inc. | 3.91 Billion TWD | 87.436% |
Tien Liang BioTech Co., Ltd. | -57.55 Million TWD | 955.525% |
Orient Pharma Co., Ltd. | 633.6 Million TWD | 22.285% |
InnoPharmax Inc. | -17.85 Million TWD | 2857.341% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | -926.77 Million TWD | 153.131% |
Excelsior Biopharma Inc. | -212.51 Million TWD | 331.706% |
DV Biomed Co., Ltd. | 160.7 Million TWD | -206.413% |
Foresee Pharmaceuticals Co., Ltd. | -781.42 Million TWD | 163.014% |
Handa Pharmaceuticals, Inc. | -653.8 Million TWD | 175.314% |
UniPharma Co., Ltd. | -68.36 Million TWD | 820.239% |
Alar Pharmaceuticals Inc. | -738.05 Million TWD | 166.717% |
Winston Medical Supply Co., Ltd. | -191.81 Million TWD | 356.715% |
Mercury Biopharmaceutical Corporation | -1.94 Million TWD | 25416.504% |
Bioray Biotech Co., Ltd | -27.23 Million TWD | 1908.189% |
TSH Biopharm Corporation Limited | -568.74 Million TWD | 186.578% |